Report cover image

Tumor Necrosis Factor Inhibitor Drug Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 128 Pages
SKU # APRC20352757

Description

Summary

According to APO Research, the global Tumor Necrosis Factor Inhibitor Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Tumor Necrosis Factor Inhibitor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Tumor Necrosis Factor Inhibitor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Tumor Necrosis Factor Inhibitor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Tumor Necrosis Factor Inhibitor Drug include UCB, Shanghai Pharmaceuticals Holding Co., Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Amgen Inc., AbbVie Inc. and PROBIOMED, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Tumor Necrosis Factor Inhibitor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Necrosis Factor Inhibitor Drug.

The report will help the Tumor Necrosis Factor Inhibitor Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Tumor Necrosis Factor Inhibitor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tumor Necrosis Factor Inhibitor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Tumor Necrosis Factor Inhibitor Drug Segment by Company

UCB
Shanghai Pharmaceuticals Holding Co., Ltd.
Johnson & Johnson
Novartis AG
Merck & Co., Inc.
Pfizer, Inc.
Amgen Inc.
AbbVie Inc.
PROBIOMED
LEO Pharma
EPIRUS Biopharmaceuticals
CASI Pharmaceuticals
Tumor Necrosis Factor Inhibitor Drug Segment by Type

Humira
Enbrel
Biosimilars
Cimzia
Simponi
Remicade
Tumor Necrosis Factor Inhibitor Drug Segment by Application

Juvenile Idiopathic Arthritis
Psoriatic Arthritis
Rheumatoid Arthritis
Ulcerative Colitis
Crohn’s Disease
Others
Tumor Necrosis Factor Inhibitor Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Inhibitor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Inhibitor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Inhibitor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Tumor Necrosis Factor Inhibitor Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Tumor Necrosis Factor Inhibitor Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Tumor Necrosis Factor Inhibitor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

128 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Tumor Necrosis Factor Inhibitor Drug Market Size (2020-2031)
2.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales (2020-2031)
2.2.3 Global Tumor Necrosis Factor Inhibitor Drug Market Average Price (2020-2031)
2.3 Tumor Necrosis Factor Inhibitor Drug by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Humira
2.3.3 Enbrel
2.3.4 Biosimilars
2.3.5 Cimzia
2.3.6 Simponi
2.3.7 Remicade
2.4 Tumor Necrosis Factor Inhibitor Drug by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Juvenile Idiopathic Arthritis
2.4.3 Psoriatic Arthritis
2.4.4 Rheumatoid Arthritis
2.4.5 Ulcerative Colitis
2.4.6 Crohn’s Disease
2.4.7 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Tumor Necrosis Factor Inhibitor Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Tumor Necrosis Factor Inhibitor Drug Revenue of Manufacturers (2020-2025)
3.4 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Manufacturers (2020-2025)
3.5 Global Tumor Necrosis Factor Inhibitor Drug Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Product Type & Application
3.8 Global Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Established Date
3.9 Global Tumor Necrosis Factor Inhibitor Drug Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 UCB
4.1.1 UCB Company Information
4.1.2 UCB Business Overview
4.1.3 UCB Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.1.4 UCB Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.1.5 UCB Recent Developments
4.2 Shanghai Pharmaceuticals Holding Co., Ltd.
4.2.1 Shanghai Pharmaceuticals Holding Co., Ltd. Company Information
4.2.2 Shanghai Pharmaceuticals Holding Co., Ltd. Business Overview
4.2.3 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.2.5 Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments
4.3 Johnson & Johnson
4.3.1 Johnson & Johnson Company Information
4.3.2 Johnson & Johnson Business Overview
4.3.3 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.3.5 Johnson & Johnson Recent Developments
4.4 Novartis AG
4.4.1 Novartis AG Company Information
4.4.2 Novartis AG Business Overview
4.4.3 Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.4.5 Novartis AG Recent Developments
4.5 Merck & Co., Inc.
4.5.1 Merck & Co., Inc. Company Information
4.5.2 Merck & Co., Inc. Business Overview
4.5.3 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.5.5 Merck & Co., Inc. Recent Developments
4.6 Pfizer, Inc.
4.6.1 Pfizer, Inc. Company Information
4.6.2 Pfizer, Inc. Business Overview
4.6.3 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.6.5 Pfizer, Inc. Recent Developments
4.7 Amgen Inc.
4.7.1 Amgen Inc. Company Information
4.7.2 Amgen Inc. Business Overview
4.7.3 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.7.5 Amgen Inc. Recent Developments
4.8 AbbVie Inc.
4.8.1 AbbVie Inc. Company Information
4.8.2 AbbVie Inc. Business Overview
4.8.3 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.8.4 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.8.5 AbbVie Inc. Recent Developments
4.9 PROBIOMED
4.9.1 PROBIOMED Company Information
4.9.2 PROBIOMED Business Overview
4.9.3 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.9.4 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.9.5 PROBIOMED Recent Developments
4.10 LEO Pharma
4.10.1 LEO Pharma Company Information
4.10.2 LEO Pharma Business Overview
4.10.3 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.10.4 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.10.5 LEO Pharma Recent Developments
4.11 EPIRUS Biopharmaceuticals
4.11.1 EPIRUS Biopharmaceuticals Company Information
4.11.2 EPIRUS Biopharmaceuticals Business Overview
4.11.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.11.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.11.5 EPIRUS Biopharmaceuticals Recent Developments
4.12 CASI Pharmaceuticals
4.12.1 CASI Pharmaceuticals Company Information
4.12.2 CASI Pharmaceuticals Business Overview
4.12.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2020-2025)
4.12.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolio
4.12.5 CASI Pharmaceuticals Recent Developments
5 Global Tumor Necrosis Factor Inhibitor Drug Market Scenario by Region
5.1 Global Tumor Necrosis Factor Inhibitor Drug Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Tumor Necrosis Factor Inhibitor Drug Sales by Region: 2020-2031
5.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Region: 2020-2025
5.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales by Region: 2026-2031
5.3 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region: 2020-2031
5.3.1 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region: 2020-2025
5.3.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region: 2026-2031
5.4 North America Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country
5.4.1 North America Tumor Necrosis Factor Inhibitor Drug Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2020-2031)
5.4.3 North America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country
5.5.1 Europe Tumor Necrosis Factor Inhibitor Drug Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2020-2031)
5.5.3 Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country
5.6.1 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Country (2020-2031)
5.6.3 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country
5.7.1 South America Tumor Necrosis Factor Inhibitor Drug Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2020-2031)
5.7.3 South America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country
5.8.1 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2020-2031)
5.8.3 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2020-2031)
6.1.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2020-2031) & (K Units)
6.1.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2020-2031)
6.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2020-2031)
6.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2020-2031)
6.3 Global Tumor Necrosis Factor Inhibitor Drug Price by Type (2020-2031)
7 Segment by Application
7.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2020-2031)
7.1.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2020-2031) & (K Units)
7.1.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2020-2031)
7.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2020-2031)
7.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2020-2031)
7.3 Global Tumor Necrosis Factor Inhibitor Drug Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Tumor Necrosis Factor Inhibitor Drug Value Chain Analysis
8.1.1 Tumor Necrosis Factor Inhibitor Drug Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Tumor Necrosis Factor Inhibitor Drug Production Mode & Process
8.2 Tumor Necrosis Factor Inhibitor Drug Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Tumor Necrosis Factor Inhibitor Drug Distributors
8.2.3 Tumor Necrosis Factor Inhibitor Drug Customers
9 Global Tumor Necrosis Factor Inhibitor Drug Analyzing Market Dynamics
9.1 Tumor Necrosis Factor Inhibitor Drug Industry Trends
9.2 Tumor Necrosis Factor Inhibitor Drug Industry Drivers
9.3 Tumor Necrosis Factor Inhibitor Drug Industry Opportunities and Challenges
9.4 Tumor Necrosis Factor Inhibitor Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.